Results 71 to 80 of about 6,588,977 (309)

TREX1, a predator for treating MSI‐H tumors?

open access: yesMolecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya   +2 more
wiley   +1 more source

On the Potential of the Excluded Volume and Auto-Correlation as Neuromorphometric Descriptors

open access: yes, 2005
This work investigates at what degree two neuromorphometric measurements, namely the autocorrelation and the excluded volume of a neuronal cell can influence the characterization and classification of such a type of cells.
Barbosa   +21 more
core   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

Fe3O4-PVDF Composite Network for Dendrite-Free Lithium Metal Batteries

open access: yesNanomaterials, 2023
Dendrite growth has been the main trouble preventing the practical application of Li metal anodes. Herein, we present how an Fe3O4-PVDF composite network prepared by using electrospinning has been designed to protect lithium metal anodes effectively.
Yun Ou   +5 more
doaj   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Direct Visualization of Li Dendrite Effect on LiCoO2 Cathode by In Situ TEM.

open access: yesSmall, 2018
Nonuniform and highly localized Li dendrites are known to cause deleterious and, in many cases, catastrophic effects on the performance of rechargeable Li batteries.
Zhenzhong Yang   +9 more
semanticscholar   +1 more source

Mg Doped Li–LiB Alloy with In Situ Formed Lithiophilic LiB Skeleton for Lithium Metal Batteries

open access: yesAdvanced Science, 2020
High energy density lithium metal batteries (LMBs) are promising next‐generation energy storage devices. However, the uncontrollable dendrite growth and huge volume change limit their practical applications. Here, a new Mg doped Li–LiB alloy with in situ
Chen Wu   +12 more
doaj   +1 more source

Thermally Conductive AlN‐Network Shield for Separators to Achieve Dendrite‐Free Plating and Fast Li‐Ion Transport toward Durable and High‐Rate Lithium‐Metal Anodes

open access: yesAdvanced Science, 2022
Lithium‐metal anodes suffer from inadequate rate and cycling performances for practical application mainly due to the harmful dendrite growth, especially at high currents.
Yue Guo   +7 more
doaj   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

open access: yesMolecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

open access: yesMolecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy